According to published results, a novel opioid-free pathway may provide noninferior pain management compared with an opioid-containing pathway during the perioperative period in patients undergoing ...

The University of Akron’s new Early Assurance Pathway to Nurse Anesthesia Program will ensure students meet critical program ...

Now, after 25 years of research, scientists at Vertex Pharmaceuticals figured out how to block this same pain pathway with suzetrigine, leading to a new pain medication for the FDA to approve.

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the ...